Docket: AR226-1616

All documents tagged with this AR226 identifier.

Page 1 of 1 — 2 documents
Title / Summary Year AR226 Docket Hash ID Pages
The document outlines a plan by DuPont and 3M to reduce blood sampling for C-8 (perfluorooctanoic acid, PFOA) among employees, focusing on those with direct exposure, while continuing to monitor certain individuals to assess the elimination rate of C-8 from the blood. 1982 AR226-1616 BRRD3jRy0ZRVBvQbKmEOVE31E 1
The document outlines a plan to reduce the blood sampling program for C-8 (perfluorooctanoic acid, PFOA) at DuPont and 3M, stating that no adverse health effects have been detected at current levels, while continuing to monitor specific personnel with potential exposure. 1982 AR226-1616 6M8dK4bQ0vRXm8ragDBy3Mmg 1